ArticleAdvances in therapy2026
Treatment Patterns and Perceptions of Treatment Options in Japanese Pediatric and Adolescent Patients with Atopic Dermatitis.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtopic dermatitis (AD) is a relapsing, chronic inflammatory skin condition characterized by intense itching and eczematous lesions. AD is common in pediatric patients, but treatment options are limited for these patients and data on treatment patterns are scarce. This study aimed to descriptively evaluate treatments used in pediatric AD and physician- and patient-reported perspectives of available options in real-world practice in Japan.
methodsData were drawn from the Adelphi Real World Pediatric and Adolescent AD Disease Specific Programme™, a cross-sectional survey, with retrospective data collection, of physicians and patients in Japan from July to December 2022. Physicians completed patient record forms for their next 3-10 consecutively consulting patients, collecting data on demographics and clinical characteristics, treatment regimens, and perceptions around treatment choice and satisfaction. Patients/caregivers also provided their perceptions on treatment choice and satisfaction. Analyses were descriptive.
resultsOverall, 55 physicians provided data for 537 pediatric patients, with 111 patients/caregivers also reporting data. The patient population was 63.3% (n = 340) male, and mean ± standard deviation age was 12.6 ± 4.2 years, with 54.0% (n = 290) of patients classified as pediatric (aged ≤ 14 years) and 46.0% (n = 247) adolescent (aged 15-17 years). Patient treatments included topical corticosteroids (TCS; 89.1%, n = 457/513), biologics (12.3%, n = 63/513), oral JAK-is (7.6%, n = 39/513), and immunosuppressants (1.8%, n = 9/513). Physicians reported that they believe better control could be achieved in 64.8% (n = 332) of patients compared with 93.1% (n = 81) of patients self-reporting this.
conclusionsTCS was the most common treatment in pediatric AD management, in agreement with the current guideline recommendation. Overall, most physicians and patients believed that better control could be achieved. However, in mild patients, most patients believed better control could be achieved, while physicians did not. This suggests that views of disease control, and desire for improved disease control, may differ between physicians and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.